Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism
- PMID: 15812265
- DOI: 10.1097/00004850-200505000-00005
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism
Abstract
The present study aimed to compare the effects of two currently used selective serotonin reuptake inhibitors (SSRIs) in Japan taking the individual background in 5-HTT gene-linked polymorphic region (5HTTLPR) genotype into account. Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were diagnosed with major depression. Patients with the l allele had a greater percentage reduction on the total score (P=0.059) and somatic anxiety items (P=0.026) of the 21-item Hamilton Depression Rating Scale (HAM-D) score compared to s/s genotype carriers. Paroxetine was significantly more effective than fluvoxamine in the s/s carriers, as evaluated on the percentage reduction in total score (P=0.012) and core (P=0.049) HAM-D after 4 weeks of medication, but not in the l/s carriers. These findings suggest that the genetic test may be useful in investigating the efficacy of the two SSRIs, and that normalization by the 5HTTLPR genotypes may lead to improvement of the precision of comparative analysis.
Similar articles
-
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.Mol Psychiatry. 1998 Nov;3(6):508-11. doi: 10.1038/sj.mp.4000425. Mol Psychiatry. 1998. PMID: 9857976 Clinical Trial.
-
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.Arch Gen Psychiatry. 2004 Nov;61(11):1163-9. doi: 10.1001/archpsyc.61.11.1163. Arch Gen Psychiatry. 2004. PMID: 15520364 Clinical Trial.
-
Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.J Med. 2004;35(1-6):151-62. J Med. 2004. PMID: 18084873 Clinical Trial.
-
Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse.Pharmacogenomics. 2000 Aug;1(3):335-41. doi: 10.1517/14622416.1.3.335. Pharmacogenomics. 2000. PMID: 11256582 Review.
-
Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.Drugs. 1998 Jan;55(1):85-120. doi: 10.2165/00003495-199855010-00007. Drugs. 1998. PMID: 9463792 Review.
Cited by
-
From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.Can J Psychiatry. 2014 Feb;59(2):62-75. doi: 10.1177/070674371405900202. Can J Psychiatry. 2014. PMID: 24881125 Free PMC article. Review.
-
Pharmacogenomics of antidepressant treatment effects.Dialogues Clin Neurosci. 2011;13(1):63-71. doi: 10.31887/DCNS.2011.13.1/jlicinio. Dialogues Clin Neurosci. 2011. PMID: 21485747 Free PMC article.
-
Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders.Pharmgenomics Pers Med. 2008;1:1-6. doi: 10.2147/pgpm.s4116. Epub 2008 Oct 21. Pharmgenomics Pers Med. 2008. PMID: 23226029 Free PMC article.
-
The impact of serotonin transporter (5-HTTLPR) genotype on the development of resting-state functional connectivity in children and adolescents: a preliminary report.Neuroimage. 2012 Feb 1;59(3):2760-70. doi: 10.1016/j.neuroimage.2011.10.030. Epub 2011 Oct 18. Neuroimage. 2012. PMID: 22032950 Free PMC article.
-
The promise and reality of pharmacogenetics in psychiatry.Psychiatr Clin North Am. 2010 Mar;33(1):181-224. doi: 10.1016/j.psc.2009.12.001. Psychiatr Clin North Am. 2010. PMID: 20159346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases